Michael Brady

TL;DR: In this high incidence population, daily tenofovir–emtricitabine conferred even higher protection against HIV than in placebo-controlled trials, refuting concerns that effectiveness would be less in a real-world setting.

TL;DR: These guidelines are aimed at clinical professionals directly involved in, and responsible for, HIV prevention, and at community advocates and organisations responsible for supporting HIV prevention strategies in those at risk of HIV acquisition.

TL;DR: It is shown that early and dramatic expansions of functional HIV‐specific CD4+ T lymphocyte frequencies directly ex vivo are demonstrated, indicating that, in some individuals at least, ART must be administered within a narrow window of opportunity during primary HIV‐1 infection to effect substantial immune preservation.

TL;DR: The PROUD study population are at substantially higher risk of acquiring HIV infection sexually than the overall population of GMSM attending sexual health clinics in England, and demonstrate that, despite broad eligibility criteria, the population interested in PrEP was highly selective.

TL;DR: Investigation of the impact of two interventions on testing activity across a whole sexual health economy shows that users can effectively be transitioned from face-to-face to Web-based services and that this introduces a new population of online users with different demographic and clinical profiles from those who use Web- based services spontaneously.